Double blind factorial trial of prindolol and hydrochlorothiazide in hypertension

J. P. Chalmers, P. I. Korner, D. J. Tiller, A. J. Bune, J. D. Steiner, M. J. West, L. M. Wing, J. F. Uther

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


The antihypertensive actions of the β adrenergic blocking agent, prindolol, and the diuretic, hydrochlorothiazide, were analysed in a double blind randomized 2x2 factorial trial in 16 patients. There were four eight week phases in which patients received prindolol alone, hydrochlorothiazide alone, prindolol plus hydrochlorothiazide in combination, and no treatment. Both drugs were given in fixed doses: prindolol, 10 mg three times per day; hydrochloro thiazide, 50 mg per day. Blood pressure was measured weekly, alternately at the outpatient clinic and at home. Supine mean arterial pressure (MAP) in resting patients fell from 127 mm Hg in the placebo phase to 117 mm Hg with hydrochlorothiazide alone, 116 mm Hg with prindolol alone, and 111 mm Hg with the combination of prindolol and hydrochlorothiazide. (The standard error of difference between treatments was ± 3.58.) A mean factorial effect of -7 mm Hg for hydrochlorothiazide (P<0.01) and -8 mm Hg for prindolol (P<0.01) was obtained, and the two drugs acted in an additive manner. The effects on standing blood pressure in resting patients were similar. No serious side effects were noted.

Original languageEnglish
Pages (from-to)650-653
Number of pages4
JournalMedical Journal of Australia
Issue number18
Publication statusPublished - May 1976
Externally publishedYes


Dive into the research topics of 'Double blind factorial trial of prindolol and hydrochlorothiazide in hypertension'. Together they form a unique fingerprint.

Cite this